Biofrontera IncChange company Symbol lookupSelect an option...BFRI Biofrontera IncMRNS Marinus Pharmaceuticals IncRVLP RVL Pharmaceuticals PLCNAUT Nautilus Biotechnology IncBOF BranchOut Food IncSPRC Scisparc LtdNRSN Neurosense Therapeutics LtdACNT Ascent Industries CoFATH Fathom Digital Manufacturing CorpPAYX Paychex IncGo
Change company Symbol lookup
Select an option...
BFRI Biofrontera Inc
MRNS Marinus Pharmaceuticals Inc
RVLP RVL Pharmaceuticals PLC
NAUT Nautilus Biotechnology Inc
BOF BranchOut Food Inc
SPRC Scisparc Ltd
NRSN Neurosense Therapeutics Ltd
ACNT Ascent Industries Co
FATH Fathom Digital Manufacturing Corp
PAYX Paychex Inc
Health Care : Pharmaceuticals | Small Cap Value
Company profileBiofrontera Inc. is a biopharmaceutical company. The Company is focused on commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company’s licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its principal licensed product is Ameluz, which is a prescription drug for use in combination with the BF-RhodoLED lamp series, for photodynamic therapy. In the United States, the PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses (AK) of mild-to-moderate severity on the face and scalp. The Company’s other products include Xepi for the treatment of impetigo, a common skin infection, due to Staphylococcus aureus or Streptococcus pyogenes. It is used in the United States in adults and children two months and older.
|
|
|
|
| |
| Latest Earnings Missed Consensus (Q2 ending 06/2023) | Next Earnings Announcement | ||||||
|---|---|---|---|---|---|---|---|
| Q2 Non-GAAP earnings GAAP vs. Non-GAAP EarningsTD Ameritrade displays two types of stock earnings numbers, which are calculated differently and may report different values for the same period. GAAP earnings are the official numbers reported by a company, and non-GAAP earnings are adjusted to be more readable in earnings history and forecasts. Announced August 11, 2023 | -$7.23 | Q2 Consensus of 2 analysts | -$4.61 | Difference from consensus | -56.83% | Q3 Earnings will announce | (Unconfirmed) November 22, 2023 |
Quarterly Earnings History and Estimates
Show high-low estimates
Draw trendlines
Draw up to 3 lines inside the chart.
BFRI's fiscal year ends in December
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.
Information provided by Copyright © 2023. All rights reserved.
Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.
Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.